Treatment of Acute Hemolytic Transfusion Reaction due to ABO ‐Incompatible Red Blood Cell Transfusion: A Case Report, Review of the Literature and Recommendation
- 26 August 2026
- journal article
- review article
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 41 (4) , e70173
Abstract
Although acute hemolytic transfusion reaction (AHTR) due to ABO‐incompatible red blood cell transfusion is a rare complication in high‐income countries, it is considered a medical emergency because of the severe intravascular hemolysis that can lead to major morbidity or death. AHTR can cause intravascular hemolysis, acute renal failure, disseminated intravascular coagulation (DIC), and shock, and therefore treatment should be prompted early and directed to prevent these complications. We present a case of AHTR due to ABO‐incompatible red blood cell transfusion successfully treated with high‐dose glucocorticoids, red blood cell, and therapeutic plasma exchange within 24 h. To our knowledge, there is no standard protocol for treatment of ABO‐incompatible red blood cell transfusions. We performed a review of the literature and made a recommendation for the treatment of AHTR due to ABO‐incompatible transfusion. Based on the existing literature and the presented case we advise, beside supportive measures and hemodialysis in case of renal failure, to consider more invasive therapies, such as therapeutic plasma exchange, red blood cell exchange or complement inhibiting drugs to prevent acute and long‐term complications. Daily measures of relevant laboratory parameters should be performed, and if hemolysis is apparent, repeated procedures should be considered.Keywords
This publication has 16 references indexed in Scilit:
- Plasma exchange in acute hemolytic reaction due to ABO‐incompatible erythrocyte concentrate transfusions: Single center experienceTransfusion Medicine, 2023
- Acute hemolytic transfusion reaction induced prolonged renal injury in an obstetric patient: A case reportAnnals of Medicine & Surgery, 2022
- Trend in ABO‐incompatible RBC transfusion‐related fatalities reported to the FDA, 2000‐2019Transfusion, 2020
- Examining the Role of Complement in Predicting, Preventing, and Treating Hemolytic Transfusion ReactionsTransfusion Medicine Reviews, 2019
- Hemolytic Transfusion ReactionsNew England Journal of Medicine, 2019
- A case of ABO-incompatible blood transfusion treated by plasma exchange therapy and continuous hemodiafiltrationCEN Case Reports, 2018
- Transfusion reactions: prevention, diagnosis, and treatmentThe Lancet, 2016
- Successful use of eculizumab for treatment of an acute hemolytic reaction after ABO‐incompatible red blood cell transfusionTransfusion, 2014
- Transfusion errors in New York State: an analysis of 10 years' experienceTransfusion, 2000
- Methylprednisolone inhibits the alternative and amplification pathways of complementInfection and Immunity, 1982